Open AccessWeekly Carboplatin and Paclitaxel for Ovarian Cancer: The “Finer Points”
Author(s) -
Muggia Franco
Publication year - 2021
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1002/onco.13572
Subject(s) - carboplatin , paclitaxel , medicine , ovarian cancer , oncology , schedule , chemotherapy , cancer , cisplatin , computer science , operating system
First‐line ovarian cancer platinum doublet is paclitaxel‐carboplatin. Superiority of weekly paclitaxel schedules has not been confirmed; however, a novel schedule with both drugs given weekly (days 1, 8, 15) followed by a 2‐week break may be advantageous to some.